SMA Type 2, or Spinal Muscular Atrophy Type 2, is a genetic disorder that primarily affects muscle strength and movement. It is caused by a deficiency of the SMN1 gene, which is essential for the survival of motor neurons in the spinal cord. Individuals with SMA Type 2 typically show symptoms between 6 and 18 months of age, including difficulty sitting up and reduced muscle tone. Unlike the more severe Type 1, children with SMA Type 2 can often sit independently but may require assistance for mobility as they grow. The condition is progressive, meaning muscle weakness can worsen over time. Treatment options, including gene therapy and supportive care, aim to improve quality of life and mobility.